{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T06:39:53Z","timestamp":1790750393911,"version":"4.1.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007071","name":"OncoMed Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007071","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.ygyno.2020.01.042","type":"journal-article","created":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T03:35:10Z","timestamp":1581046510000},"page":"386-391","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trial"],"prefix":"10.1016","volume":"157","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9343-8754","authenticated-orcid":false,"given":"Robert L.","family":"Coleman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katelyn F.","family":"Handley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Burger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8987-0066","authenticated-orcid":false,"given":"Graziela Zibetti Dal","family":"Molin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Stagg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil K.","family":"Sood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen N.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2020.01.042_bb0005","series-title":"GLOBOCAN 2012 Cancer Incidence and Mortality Worldwide: IARC Cancerbase No. 11","year":"2013"},{"issue":"17","key":"10.1016\/j.ygyno.2020.01.042_bb0010","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2020.01.042_bb0015","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(17)30279-6","article-title":"Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology\/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial","volume":"18","author":"Coleman","year":"2017","journal-title":"The Lancet Oncology"},{"issue":"13","key":"10.1016\/j.ygyno.2020.01.042_bb0020","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"10023","key":"10.1016\/j.ygyno.2020.01.042_bb0025","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S0140-6736(15)01167-8","article-title":"Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"387","author":"Ledermann","year":"2016","journal-title":"Lancet"},{"issue":"26","key":"10.1016\/j.ygyno.2020.01.042_bb0030","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"26","key":"10.1016\/j.ygyno.2020.01.042_bb0035","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"10.1016\/j.ygyno.2020.01.042_bb0040","doi-asserted-by":"crossref","first-page":"5188","DOI":"10.1158\/1078-0432.CCR-11-2258","article-title":"Molecular pathways: context-dependent approaches to Notch targeting as cancer therapy","volume":"18","author":"Egloff","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"7353","key":"10.1016\/j.ygyno.2020.01.042_bb0045","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Cancer Genome Atlas Research Network","year":"2011","journal-title":"Nature"},{"issue":"18","key":"10.1016\/j.ygyno.2020.01.042_bb0050","doi-asserted-by":"crossref","first-page":"6030","DOI":"10.1158\/0008-5472.CAN-10-2719","article-title":"Biological roles of the Delta family Notch ligand DLL4 in tumor and endothelial cells in ovarian cancer","volume":"71","author":"Hu","year":"2011","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.ygyno.2020.01.042_bb0055","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1158\/1535-7163.MCT-15-0144","article-title":"DLL4 inhibition plus aflibercept markedly reduces ovarian tumor growth","volume":"15","author":"Huang","year":"2016","journal-title":"Mol. Cancer Ther."},{"issue":"3","key":"10.1016\/j.ygyno.2020.01.042_bb0060","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ygyno.2005.10.036","article-title":"Phase II trial of weekly paclitaxel (80\u00a0mg\/m2) in platinum and paclitaxel resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study","volume":"101","author":"Gynecologic Oncology Group","year":"2006","journal-title":"Gynecol. Oncol."},{"issue":"7122","key":"10.1016\/j.ygyno.2020.01.042_bb0065","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1038\/nature05313","article-title":"Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis","volume":"444","author":"Ridgway","year":"2006","journal-title":"Nature"},{"issue":"7122","key":"10.1016\/j.ygyno.2020.01.042_bb0070","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1038\/nature05355","article-title":"Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis","volume":"444","author":"Noguera-Troise","year":"2006","journal-title":"Nature"},{"issue":"24","key":"10.1016\/j.ygyno.2020.01.042_bb0075","doi-asserted-by":"crossref","first-page":"6295","DOI":"10.1158\/1078-0432.CCR-14-1373","article-title":"A phase I dose escalation and expansion study of the anticancer stem cell agent demcizumab (anti-DLL4) in patients with previously treated solid tumors","volume":"20","author":"Smith","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.ygyno.2020.01.042_bb0080","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"issue":"2","key":"10.1016\/j.ygyno.2020.01.042_bb0085","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/IGC.0b013e3182070f17","article-title":"Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG)","volume":"21","author":"Rustin","year":"2011","journal-title":"Int J Gynecologic Cancer"},{"issue":"19","key":"10.1016\/j.ygyno.2020.01.042_bb0090","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1200\/JCO.2011.39.1540","article-title":"Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors","volume":"30","author":"Krop","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2020.01.042_bb0095","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s11523-017-0543-0","article-title":"Phase IB trial of the anti-cancer stem cell DLL4-binding agent demcizumab with pemetrexed and carboplatin as first-line treatment of metastatic non-squamous NSCLC","volume":"13","author":"McKeage","year":"2018","journal-title":"Target. Oncol."},{"issue":"32","key":"10.1016\/j.ygyno.2020.01.042_bb0100","doi-asserted-by":"crossref","first-page":"3836","DOI":"10.1200\/JCO.2015.63.1408","article-title":"Bevacizumab combined with weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan in platinum-resistant recurrent ovarian cancer: analysis by chemotherapy cohort of the randomized phase III AURELIA trial","volume":"33","author":"Poveda","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.ygyno.2020.01.042_bb0105","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S1470-2045(11)70244-3","article-title":"Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer","volume":"12","author":"Coleman","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ygyno.2020.01.042_bb0110","series-title":"Mereo BioPharma Receives FDA Fast Track Designation for Navicixizumab for the Treatment of Heavily Pretreated Ovarian Cancer [Press Release]","year":"2019"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825820300950?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825820300950?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:51:41Z","timestamp":1758772301000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825820300950"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S0090825820300950"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.01.042","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trial","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.01.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}